My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 690

    1.

    Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

    Diabetes Care. 2006 Jun;29(6):1220-6.PMID: 16731999 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

    N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.PMID: 15755765 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

    Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

    Lancet. 2006 Sep 9;368(9539):919-28.PMID: 16962881 [PubMed - indexed for MEDLINE]Related articles

    4.

    Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

    Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators.

    Ann Intern Med. 2007 Jul 3;147(1):1-9.PMID: 17606955 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

    JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

    LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators.

    Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.PMID: 17719314 [PubMed - indexed for MEDLINE]Related articles

    7.

    Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

    Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.

    Curr Med Res Opin. 2002;18(4):220-8.PMID: 12201623 [PubMed - indexed for MEDLINE]Related articles

    8.

    Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.

    Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V; TNT Steering Committee and Investigators.

    Heart. 2008 Apr;94(4):434-9. Epub 2007 Dec 10.PMID: 18070940 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

    Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM.

    J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. Epub 2006 Oct 17.PMID: 17084252 [PubMed - indexed for MEDLINE]Related articles

    10.

    Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.

    Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group.

    Clin Ther. 2004 Nov;26(11):1821-33.PMID: 15639694 [PubMed - indexed for MEDLINE]Related articles

    11.

    Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    Arca M.

    Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

    12.

    Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

    Lancet. 2004 Aug 21-27;364(9435):685-96.PMID: 15325833 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.

    Diabetes Care. 2006 Jul;29(7):1478-85.PMID: 16801565 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators.

    J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54.PMID: 18402899 [PubMed - indexed for MEDLINE]Related articles

    15.

    Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

    Arca M, Gaspardone A.

    Drugs. 2007;67 Suppl 1:29-42. Review.PMID: 17910519 [PubMed - indexed for MEDLINE]Related articles

    16.

    Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.

    Koren MJ, Hunninghake DB; ALLIANCE Investigators.

    J Am Coll Cardiol. 2004 Nov 2;44(9):1772-9.PMID: 15519006 [PubMed - indexed for MEDLINE]Related articles

    17.

    HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

    Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators.

    N Engl J Med. 2007 Sep 27;357(13):1301-10.PMID: 17898099 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

    Am J Kidney Dis. 2009 May;53(5):741-50. Epub 2009 Feb 11.PMID: 19216014 [PubMed - indexed for MEDLINE]Related articles

    19.

    Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).

    März W, Wollschläger H, Klein G, Neiss A, Wehling M.

    Am J Cardiol. 1999 Jul 1;84(1):7-13.PMID: 10404843 [PubMed - indexed for MEDLINE]Related articles

    20.

    Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.

    Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC.

    J Am Coll Cardiol. 2008 May 20;51(20):1938-43.PMID: 18482661 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity